MG-K10 not checked
Shanghai Mabgeek Biotech.Co.Ltd
FollowEvery change as it happens, and a Monday email
Trials
10 active
14 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “loading dose (SC) at Week 0, followed by a single dose Q2W through Week 52”In the company’s words, NCT07540442 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis (3 trials), Prurigo Nodularis, Dermatitis, Atopic, Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Spontaneous Urticaria (CSU), Atopic Eczema, Seasonal Allergic Rhinitis and 1 more
- Main trialPhase 3
- “A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.”In the company’s words, NCT06779136 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis
- ICP-332Beijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- UpadacitinibAbbVie · Phase 3
- OPA-15406Otsuka · Phase 3
- GX-03Turn Therapeutics · Phase 2/3
- VC005Jiangsu vcare pharmaceutical technology co., LTD · Phase 3
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
Coming up7
- 5 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 7 May 2027Phase 2 trial completes · ClinicalTrials.gov
- 15 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 21 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- Jan 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 16 NovNew trial: none to Phase 1/2 · ClinicalTrials.gov NCT07938606
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2026 | Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis | |
| Phase 3Not yet recruiting | 5 Jan 2027 | A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | |
| Phase 3Recruiting | 15 Nov 2027 | Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma | |
| Phase 3Not yet recruiting | 21 Dec 2027 | A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps | |
| Phase 3Not yet recruiting | 31 Mar 2028 | A Study of MG-K10 in Chronic Spontaneous Urticaria | |
| Phase 3Not yet recruiting | Jan 2029 | A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis | |
| Phase 2/3Recruiting | 31 May 2025 | Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis | |
| Phase 2Not yet recruiting | 7 May 2027 | A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria | |
| Phase 1/2Recruiting | May 2025 | IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients | |
| Phase 1/2Not yet recruiting | Dec 2027 | MG-K10 in Pediatric Atopic Dermatitis (6-12 Years) | |
| Phase 3Unknown | 11 Jun 2025 | Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis | |
| Phase 2Unknown | 22 Sep 2023 | A Study of MG-K10 in Subjects With Atopic Dermatitis | |
| Phase 2Completed | 9 Mar 2026 | A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis | |
| Phase 1/2Unknown | 20 Dec 2023 | A Study of MG-K10 in Subjects With Asthma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026